Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer
Abstract
Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors have a somatic missense mutation in the nucleotide excision repair (NER) gene, ERCC2, which confers increased sensitivity to cisplatin-based chemotherapy. However, a significant subset of patients is ineligible to receive cisplatin-based therapy due to medical contraindications, and no NER-targeted approaches are available for platinum-ineligible or platinum-refractory ERCC2-mutant cases.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 18, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-3316
Entities
People
- Amruta S. Samant
- David B Solit
- David J. Konieczkowski
- David Liu
- Dávid Szüts
- Eliezer M. Van Allen
- Elizabeth R. Plimack
- Gopa Iyer
- Helle Pappot
- István Csabai
- James A. Rodrigues
- Jean H. Hoffman-censits
- Jean-bernard Lazaro
- Jonathan E Rosenberg
- Judit Börcsök
- Kasia M. Dillon
- Kent W. Mouw
- Mary-ellen Taplin
- Miklos Diossy
- Naresh Vasani
- Orsolya Rusz
- Raie Bekele
- Rita Lozsa
- Sizhi P. Gao
- Sándor Spisák
- Søren Brunak
- Viktoria Tisza
- Zoltán Szállási
- Zoë J. Frazier
- Zsófia Sztupinszki
Organizations
- Boston Children's Hospital
- Brigham and Women's Hospital
- Dana–Farber Cancer Institute
- Eötvös Loránd University
- Fox Chase Cancer Center
- Johns Hopkins University
- Memorial Sloan Kettering Cancer Center
- Novo Nordisk Fonden
- Ohio State University
- Semmelweis University
- The Breast Cancer Research Foundation
- The Velux Foundations
- University of Copenhagen